Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: Other
Life Threatening? No
Write-up: Information was received from Sanofi Pasteur MSD (MCN #: DK-1577272925-2016009199) on 15-SEP-2016. Case received from a physician via HA on 12-Sep-2016 under the reference number DK-DKMA-WBS-0004427. A 12-year-old female adolescent patient received GARDASIL, (batch number Lot unknown, Dose 1) via intramuscular route in Dec-2008, GARDASIL, (batch number Lot unknown, Dose 2) via intramuscular route on 07-Jan-2009, GARDASIL, (batch number Lot unknown, Dose 3) via intramuscular route on 06-May-2009. The patient experienced Headache, Dizziness, Palpitation, Nausea, Abdominal pain, Voiding difficulty, Shortness of breath, Sleep disorder, Cognitive disorders, weakness of legs, frequent flu, frequent sore throat, frequent cystitis, Temperature regulation disorder, Muscle pain, Joint pain, Dry eyes, Dry mouth, Diarrhea, Obstipation, Migraine with aura, Frequent absence from school (due to illness), depression and Anxiety on an unknown date. Case description: The patient states that her first symptoms started after the first vaccination, with headache. She has later been diagnosed with migraine with aura, something she suffers from daily. The other symptoms have developed subsequently. At the time of vaccination, the patient played badminton twice weekly and was boxing twice weekly. As a consequence of her symptoms, the patient has also developed depression and anxiety. Her absence from school was commented upon. She has also nearly been expelled from high school due to 2 months sick leave, after which she has only been able to attend 4 hours per day for a couple of months. Other vaccines or medications: unknown. The patient''s outcome was reported as Not Recovered/Not Resolved.
Copyright © 2018 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166